Cargando…
POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy
Autores principales: | Chen, Yan‐Xing, Wang, Zi‐Xian, Yuan, Shu‐Qiang, Jiang, Teng‐Jia, Huang, You‐Sheng, Xu, Rui‐Hua, Wang, Feng, Zhao, Qi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473642/ https://www.ncbi.nlm.nih.gov/pubmed/34586735 http://dx.doi.org/10.1002/ctm2.524 |
Ejemplares similares
-
Recommendations for the classification of germline variants in the exonuclease domain of POLE and POLD1
por: Mur, Pilar, et al.
Publicado: (2023) -
Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps
por: Elsayed, Fadwa A., et al.
Publicado: (2019) -
POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East
por: Siraj, Abdul K., et al.
Publicado: (2020) -
POLE/POLD1 mutation and tumor immunotherapy
por: Ma, Xiaoting, et al.
Publicado: (2022) -
Non-Exonuclease Domain POLE Mutations Associated with Immunotherapy Benefit
por: Dong, Sharlene, et al.
Publicado: (2022)